ORGANIC
LETTERS
2010
Vol. 12, No. 5
1008-1011
Organocatalytic Asymmetric Formal
[4 + 2] Cycloaddition for the Synthesis of
Spiro[4-cyclohexanone-1,3′-oxindoline]
Derivatives in High Optical Purity
Qiang Wei and Liu-Zhu Gong*
Hefei National Laboratory for Physical Sciences at the Microscale and Department of
Chemistry, UniVersity of Science and Technology of China, Hefei 230026, China
Received January 4, 2010
ABSTRACT
A bifunctional organocatalytic asymmetric formal [4 + 2] cycloaddition reaction of Nazarov reagents and methyleneindolinones afforded
spiro[4-cyclohexanone-1,3′-oxindoline] derivatives with excellent enantioselectivity (up to 98% ee).
The spiro[4-cyclohexane-1,3′-oxindoline] structural motif is
commonly present in a number of natural products as
exemplified by gelsemium and marcfortine alkaloids.1,2 It
also comprises a core component of various biologically
active compounds.3 Recently, they have been found serving
as antagonists of MDM2 interactions and hence hold great
potential to be selective and potent anticancer agents.4 In
the past several years, significant advances have been
achieved on the development of synthetic methods to access
spirooxindole derivatives with a concomitant creation of an
all-carbon quaternary stereogenic center in an enantioselec-
tive manner.5 Overman pioneered an asymmetric intramo-
lecular Heck reaction rendering the synthesis of spiro[pyr-
rolidin-3,3′-oxindole] derivatives with high enantiomeric
purity.6 Trost developed an elegant asymmetric alkylation
reaction of an oxindole enolate enabling a concise synthesis
of horsfiline.7 Recently, Barbas and Melchiorre independently
reported organocatalytic conjugate addition reactions of
3-substituted oxindoles to electronically deficient olefins
creating an all-carbon stereogenic center with high levels of
stereochemical control.8 Chen and co-workers presented a
(5) For reviews, see: (a) Marti, C.; Carreira, E. M. Eur. J. Org. Chem.
2003, 2209. (b) Douglas, C. J.; Overman, L. E. Proc. Natl. Acad. Sci. U.S.A.
2004, 101, 5363. (c) Trost, B. M.; Jiang, C. Synthesis 2006, 369. (d)
Galliford, C. V.; Scheidt, K. A. Angew. Chem., Int. Ed. 2007, 46, 8748.
(6) (a) Ashimori, A.; Overman, L. E. J. Org. Chem. 1992, 57, 4571. (b)
Ashimori, A.; Bachand, B.; Overman, L. E.; Poon, D. J. J. Am. Chem. Soc.
1998, 120, 6477. (c) Matsuura, T.; Overman, L. E.; Poon, D. J. J. Am.
Chem. Soc. 1998, 120, 6500. (d) Overman, L. E.; Rosen, M. D. Angew.
Chem., Int. Ed. 2000, 39, 4596. (e) Dounay, A. B.; Hatanaka, K.; Kodanko,
J. J.; Oestreich, M.; Overman, L. E.; Pfeifer, L. A.; Weiss, M. M. J. Am.
Chem. Soc. 2003, 125, 6261.
(1) (a) Saxton, J. E. Nat. Prod. Rep. 1992, 9, 393. (b) Takayama, H.;
Sakai, S.-J. In The Alkaloids; Cordell, G. A., Ed.; Academic Press: New
York, 1997; Vol. 49, pp 1-78.
(2) (a) Polousky, J.; Merrien, M.-A.; Prange´, T.; Pascard, C.; Moreau,
S. J. Chem. Soc., Chem. Commun. 1980, 601. (b) Prange´, T.; Billion, M.-
A.; Vuilhorgne, M.; Pascard, C.; Polonsky, J.; Moreau, S. Tetrahedron Lett.
1981, 22, 1977. (c) Yamazaki, M.; Okuyama, E.; Kobayashi, M.; Inoue,
H. Tetrahedron Lett. 1981, 22, 135
.
(3) (a) Fensome, A.; Koko, M.; Wrobel, J.; Zhang, P.; Zhang, Z.; Cohen,
J.; Lundeen, S.; Rudnick, K.; Zhu, Y.; Winneker, R. Bioorg. Med. Chem.
Lett. 2003, 13, 1317. (b) Venkatesan, H.; Davis, M. C.; Altas, Y.; Snyder,
J. P.; Liotta, D. C. J. Org. Chem. 2001, 66, 3653. (c) Mah, S. C.; Hofbauer,
K. G. Drugs of the Future 1987, 12, 1055.
(7) (a) Trost, B. M.; Cramer, N.; Bernsmann, H. J. Am. Chem. Soc.
2007, 129, 3086. (b) Trost, B. M.; Cramer, N.; Silverman, S. M. J. Am.
Chem. Soc. 2007, 129, 12396.
(8) (a) Bui, T.; Syed, S.; Barbas, C. F., III. J. Am. Chem. Soc. 2009,
131, 8758. (b) Galzerano, P.; Bencivenni, G.; Pesciaioli, F.; Mazzanti, A.;
Giannichi, B.; Sambri, L.; Bartoli, G.; Melchiorre, P. Chem.sEur. J. 2009,
15, 7846.
(4) Liu, J.-J.; Zhang, Z. (Hoffmann-LaRoche AG), PCT Int. Appl.
WO2008/055812, 2008.
10.1021/ol100020v 2010 American Chemical Society
Published on Web 02/04/2010